The Vascular Endothelial Growth Factor C pipeline drugs market research report outlays comprehensive information on the Vascular Endothelial Growth Factor C targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Vascular Endothelial Growth Factor C pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Ophthalmology, Oncology, and Undisclosed which include the indications Wet (Neovascular / Exudative) Macular Degeneration, Diabetic Macular Edema, Solid Tumor, Retinoblastoma, and Unspecified. It also reviews key players involved in Vascular Endothelial Growth Factor C targeted therapeutics development with respective active and dormant or discontinued products.
The Vascular Endothelial Growth Factor C pipeline targets constitutes close to ten molecules. Out of which, approximately ten molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, and Preclinical stages are 2, 2, 2, and 4 respectively.
Vascular Endothelial Growth Factor C overview
Vascular Endothelial Growth Factor C (VEGFC) is a member of the platelet-derived growth factor/vascular endothelial growth factor (PDGF/VEGF) family. The proprotein is cleaved into an active form that can bind and activate VEGFR-2 and VEGFR-3 receptors. It promotes angiogenesis and endothelial cell growth, and can also affect the permeability of blood vessels.
For a complete picture of Vascular Endothelial Growth Factor C’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
